Sangamo BioSciences Inc
Most Recent
Company & Industry Overviews.Sangamo Therapeutics Rises on Positive Clinical Trial Results
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from their Phase 1/2 ALTA trial.
Company & Industry Overviews.Comparing Sangamo’s and Amarin’s Revenue Growth
Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively.
Company & Industry Overviews.Analysts’ Recommendations for Sangamo Therapeutics and Amarin
On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55.
Company & Industry Overviews.How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
Company & Industry Overviews.A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Company & Industry Overviews.Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
Company & Industry Overviews.CRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.
Company & Industry Overviews.Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Company & Industry Overviews.Sangamo Therapeutics: The Promise of Zinc Fingers
For fiscal 2018 and fiscal 2019, Sangamo is expected to generate revenues of $82.73 million and $89.39 million, respectively.
Company & Industry Overviews.A Financial Overview of Intellia Therapeutics in September
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.
Company & Industry Overviews.How CRISPR Therapeutics Is Positioned in September
CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.
Company & Industry Overviews.Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
Company & Industry Overviews.Why Sangamo Therapeutics Stock Is Down More than 22% Today
Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.
Earnings Report.Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
Company & Industry Overviews.CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Healthcare.Exploring Collaboration between Pfizer and Sangamo Therapeutics
On January 3, Pfizer and Sangamo Therapeutics announced a collaboration for developing a potential gene therapy for the treatment of ALS.
Healthcare.Pfizer and Sangamo Therapeutics: Hemophilia A Gene Therapy
In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy, which includes SB-525.
Company & Industry Overviews.Pfizer on the Street: Analyst Recommendations in February 2018
In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a key collaboration agreement.
Earnings Report.What Investors Should Know about Pfizer’s Recent Developments
The recent developments for Pfizer (PFE) include various product developments, pipeline developments, and commercial developments.
Company & Industry Overviews.Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
Company & Industry Overviews.The Evolution of Hemophilia Treatment—And What It Means for BioMarin
BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.
Company & Industry Overviews.Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?
Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.
Company & Industry Overviews.How Could Baxalta Acquisition Become a Catalyst for Shire?
Shire’s (SHPG) acquisition of Baxalta could prove to be a catalyst for Shire’s valuation in the near term. The combined entity is expected to record revenues of $20 billion by fiscal 2020.
Company & Industry Overviews.BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data
On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.